Jeito Capital, a prominent European biotech investor, raised $1.2 billion for its next fund (Jeito II), positioning it as the largest ever for a fully independent European fund focused on biopharma. Jeito said the new financing will support 15 to 20 clinical-stage companies. The fund build reflects investor appetite for later-stage innovation while emphasizing portfolio-level independence. Jeito noted it plans to increase average investment size up to roughly €150 million per company, aiming to accelerate programs into advanced clinical development. The close follows Jeito’s first fund and comes amid ongoing concerns that Europe struggles to scale life science innovation and retain IP-driven growth. Jeito’s messaging directly ties the fund to “patient-driven investment” and future market access. For European startups and midcaps, the fundraising widens the runway for programs requiring sustained clinical capital beyond early seed rounds.